Cygnus GlucoWatch Launch Contingent On AutoSensor Facility Clearance
This article was originally published in The Gray Sheet
Executive Summary
Full-scale U.S. launch of Cygnus' GlucoWatch Biographer non-invasive glucose monitoring system will await FDA approval of a primary manufacturing site for the AutoSensor component, the firm says.
You may also be interested in...
Respironics Investors Breathing Easy After Turnaround; Stock Up 25% In Nov.
An accelerating growth rate and positive news highlighted at Respironics' Nov. 16 annual shareholder meeting breathed new life into the company's stock price. The issue closed Nov. 30 at $24.56, up $4.93, or 25.1%, for the month.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.